Vascular Precision- ! SECOND PLACE !
Contact: Michael Gober
gober_michael@gsb.stanford.edu

[ back to top ]

 

Affinity Vision
Contact: David Bergstein
David.Bergstein.2002@alum.bu.edu

Affinity Vision is revolutionizing microarray use with label-free detection technologies. Our microarray detection technologies free scientists and doctors from the burden of labeling their molecular targets. Avoiding the need to label saves time, money, and most importantly, opens the door to many new and exciting applications for microarrays.
[ back to top ]

Amorigen Pharmaceuticals
Contact: John J. Frey
jfrey@hpdtech.com

Amorigen Pharmaceuticals is developing a predictive-pharmacology-driven product pipeline engine of repositioned prescription drugs treating psychiatric or psychological conditions with quality-of-life or lifestyle ramifications, targeting unmet medical needs (no present FDA approved therapy) with potential to be first-in-class. Now ready to advance into phase 2 clinical trials by leveraging the existing IND (Investigational New Drug dossier filed with the FDA) for a compound that has been marketed for a distinct indication (no generic competition due to a patented form-of-administration), based on our pending use-patent for low-dose, p.r.n.- administered drug that treats the psychogenic root-cause of four related disorders, each with peak annual revenue potential of up to or exceeding $500 million. We are currently negotiating a global Pharma strategic partnership that funds launch and sales/marketing, and we receive development milestone payments plus significant royalty-on-salesin addition to co-marketing rights; thus we expect to achieve profitability
by year-four.
[ back to top ]

---

BioSignetics
Contact: Vladimir Polyshcuk, Ph.D.
vladpoly@bsignetics.com

CorInnova, Inc.
Contact: Dr. John C. Criscione
Corinnova@cox-internet.com

CorInnova Incorporated is an early stage biomedical device company that is engaged in the development of technologies that lead to heart recovery. In particular, recent discoveries indicate that aberrant heart motions such
as dyskinesis and hypokinesis can lead to muscle cell death, fibrosis, infarct expansion, and heart failure; whereas restoration of normal cardiac motion can preserve vulnerable heart tissue and promote recovery. Our approach is called Cardiac ReKinesis (CRK) Therapy; and to so treat the annual 70,000 vulnerable, bedridden Americans with severe cardiac dyskinesis, we have developed the CRK Pocket, an active direct cardiac compression device that can be implanted and explanted in a minimally invasive fashion.
[ back to top ]

Cure Works
Product/Service: Vaccine Formulation Venture
Contact: Philip Dreyfuss
dreyfuss@fas.harvard.edu

Malaria is one of the most severe public health problems in the world. There is no known cure for the disease and current treatments are ineffective and insufficient. CureWorks, Inc. has identified a novel approach to developing a malaria vaccine based on cutting-edge nanoscale drug-delivery technology. CureWorks, Inc. will initially target the rapidly growing travelers’ vaccine market and then use the expertise developed to extend into other vaccine and therapeutic applications.
[ back to top ]

---

ImmunoGenetix Therapeutics
Contact: Jim Laufenberg
lauf1@earthlink.com

ImmunoGenetix Therapeutics, Inc. is an early stage biotechnology company developing advanced DNA-based therapies for the treatment of viral infections, with a focus on HIV, and has exclusive worldwide rights to proprietary therapeutic candidates being developed at the University of Kansas Medical Center. A lead candidate has completed initial efficacy studies in monkeys with promising results. The company is now prepared to process a Proposal for a major NIH drug development contract in order to complete an IND submission.
[ back to top ]

---

Keren Pharmaceuticals
Contact: David Dreyfuss
dhdreyfus@pol.net

Keren Pharmaceutical is a seed stage biotechnology company that uses EGS (External Guide Sequence) RNA enzyme technology to develop inhaled drugs for influenza, asthma and other respiratory diseases. It has exclusive rights from Yale University to the technology, which was developed by Nobel Prize winner Sidney Altman.
[ back to top ]

---

Linguaflex
Contact: Andrew Scirri
andrewscirri@yahoo.com

Linguaflex is a medical device company that will develop, manufacture and distribute novel medical devices for the treatment of sleep apnea. Our goal is to be the market leader in providing minimally invasive treatments that address the root cause of sleep apnea. The initial company focus is on product development and gaining FDA approval. Linguaflex will also market and sell complementary and peripheral products for our device.
[ back to top ]

---

Microbiobotics
Contact: Alexander Kim
mbb@kirns.de

MBB will release the Cell Surgeon as its flagship product. It eliminates the incredibly tedious, unreliable, often cell-damaging and expensive process that biologists face. We envision becoming a leader for MEMS robotics by building a technology platform with our fundamental patents and integrate tools for specific markets such as agriculture, tissue engineering, genomics and personalized medicine.
[ back to top ]

---

Molecular Creativity
Contact: David R. Bachinsky
dbachinsky@comcast.net

Molecular Creativity, Inc. is dedicated to providing unique DNA products and services. Internal research and development at Molecular Creativity,Inc. has focused on a novel, two compartment approach to storage of biologicals. Core technologies are focused on the storage of DNA and other biologicals with applications to multiple markets including medical, military, forensics, biobanks and Jewelry.
[ back to top ]

---

Osio Corporation
Contact: Alberto Osio
alosio@sloan.mit.edu

Osio Corp's patent pending Topical Presbyopia Procedure (TOPP) is the only safe, non-invasive and effective procedure available to treat presbyopes or "short arms disease" (up-close vision loss) using an ingenious combination of personalized contact lenses, specially formulated eye drops and integrating specification software. TOPP has already completed the discovery phase and controlled trials with 150 successful treatments under the supervision of its inventor. The next stage of development will be to pursue United States Food and Drug Administration (FDA) approval before
launching commercially to every optical retail outlets (i.e. Lens Crafters) and eye clinics across the US.
[ back to top ]

---

Previva, Inc.
Contact: Murat Kalayoglu
murat_k@mit.edu

Previva, Inc. develops real-time, remote systems to monitor patients’ medication use and prevent complications from chronic diseases. Our lead product, VentStar, controls asthma and similar pulmonary diseases that afflict 24 million Americans and incur annual costs of over $27 billion. VentStar uses a proprietary “smart inhaler” to predict asthma attacks and prevent them with early, low-cost interventions. VentStar saves lives, reduces hospital admissions, and reduces healthcare costs while building a substantial and forecastable recurring revenue stream. Previva represents an excellent opportunity to build a profitable business on a chronic disease population that will double by 2020.
[ back to top ]

---

SeeScienceRun
Contact: Philip Dreyfuss
dreyfuss@fas.harvard.edu

Protocols are the recipes for scientific experiments. Just as the average cook has difficulty following the written recipe of a master chef, it is challenging and often impossible for scientists to take a text-based protocol and get the desired experimental result. Performing a scientific procedure for the first time or reproducing a protocol from the scientific literature can be an extremely time consuming and frustrating experience. SeeScienceRun.com seeks to alleviate this difficulty by taking advantage of the fact that many key aspects of experimental protocols can be more readily conveyed visually than through words. We will produce, sell and distribute high quality streaming demonstration videos that illustrate fundamental and modern experimental techniques.
[ back to top ]

---

SimuGen
Contact: Daniel Sheehan
ds394@cam.ac.uk

SimuGen is a gene profiling company, implementing novel techniques from the field of Computational Biology and bringing to market a kit that can determine substance toxicity cheaper, faster and better than animal models.
[ back to top ]